Kawasaki Disease

Kawasaki Disease – High‑Yield Study Guide for Medical Students

Definition

Kawasaki disease (KD) is an acute, self-limited, medium-vessel vasculitis of childhood, characterized by fever and mucocutaneous inflammation, with a particular predilection for the coronary arteries leading to coronary artery aneurysms if untreated.^[1] It is a leading cause of acquired heart disease in children in developed countries.

Epidemiology

Kawasaki disease occurs worldwide but has the highest incidence in East Asian populations, particularly in Japan. It predominantly affects children <5 years, with a peak between 6 months and 2 years of age. There is a slight male predominance (≈1.5:1). Seasonal variation is often observed (winter–spring peaks), and cases can cluster in epidemics, suggesting an infectious trigger in genetically susceptible hosts.^{[1], [2]}

Pathophysiology

The exact etiology is unknown, but KD is thought to result from an abnormal immune response to an infectious or environmental trigger in genetically predisposed children. This leads to systemic inflammation and immune-mediated injury of medium-sized arteries, especially the coronary arteries.

Endothelial cells (ECs) are central to KD pathophysiology. There is activation and injury of the endothelium with infiltration by neutrophils, monocytes, and lymphocytes, cytokine release (e.g., IL-1, IL-6, TNF-α), and upregulation of adhesion molecules. This results in pan-vasculitis, destruction of the internal elastic lamina, and myofibroblastic proliferation in the vascular wall, which together promote coronary artery dilatation and aneurysm formation.^{[3], [2]}

There is increasing recognition of overlapping mechanisms with other pediatric inflammatory syndromes, including MIS-C (Multisystem Inflammatory Syndrome in Children) associated with SARS‑CoV‑2, but KD remains a distinct entity with characteristic coronary involvement and age distribution.^{[4], [1]}

Clinical Presentation

The classic presentation is a young child with high, persistent fever and a constellation of mucocutaneous and lymph node findings. The disease classically evolves through acute, subacute, and convalescent phases.

Classic (Complete) Kawasaki Disease Criteria

Diagnosis of classic (complete) KD is based on:

• Fever ≥5 days (often >39°C, minimally responsive to antipyretics) plus
• ≥4 of the following 5 principal clinical features (other diagnoses excluded):^[1]
  • Conjunctivitis: Bilateral, nonexudative bulbar conjunctival injection, typically sparing the limbus.
  • Oral mucous membrane changes: Diffuse erythema of oral mucosa, "strawberry tongue" (erythematous tongue with prominent papillae), red, cracked lips.
  • Peripheral extremity changes: Erythema and edema of hands and feet in the acute phase; periungual desquamation (peeling) in the subacute phase.
  • Polymorphous rash: Nonvesicular, polymorphous rash (morbilliform, urticarial, erythema multiforme-like), usually starting on trunk.
  • Cervical lymphadenopathy: Usually unilateral, ≥1.5 cm in diameter, non-suppurative.

Other Clinical Features

Additional findings that support the diagnosis but are not part of the classic criteria include:

• Cardiovascular: Tachycardia, gallop, decreased LV function, pericardial effusion, valvulitis (often mitral regurgitation), coronary artery dilatation or aneurysms.
• Gastrointestinal: Vomiting, diarrhea, abdominal pain, hydrops of gallbladder, elevated liver enzymes.
• Hematologic: Thrombocytosis in subacute phase, anemia.
• Musculoskeletal: Arthralgia or arthritis (often large joints).
• Genitourinary: Sterile pyuria, urethritis.
• Neurological: Irritability is very common; in rare cases, complications like aseptic meningitis. Very rarely, conditions such as Grisel’s syndrome (non-traumatic atlantoaxial subluxation) may appear as early manifestations and can precede severe forms like KD shock syndrome (KDSS).^[5]

Special Clinical Forms

• Incomplete (atypical) Kawasaki disease: Fever ≥5 days plus only 2–3 of the principal features, but with supportive laboratory and echocardiographic findings. This form is particularly common in infants <6 months and is highly relevant because it carries a higher risk of coronary complications if missed.^[1]
• Kawasaki disease shock syndrome (KDSS): A severe form characterized by hypotension, signs of poor perfusion, and myocardial dysfunction or distributive shock, often requiring intensive care. KDSS can be associated with higher inflammatory markers and increased risk of coronary abnormalities.^{[5], [1]}
• KD-associated macrophage activation syndrome (KD-MAS): A hyperinflammatory complication with cytopenias, coagulopathy, liver dysfunction, hyperferritinemia, and high mortality risk; classification and management increasingly incorporate sJIA-MAS criteria and step-up immunomodulation strategies.^[6]

Diagnosis

Kawasaki disease is a clinical diagnosis, supported by laboratory and echocardiographic findings. There is no single diagnostic test.

Laboratory Findings

• Inflammatory markers: Elevated ESR and CRP are typical.
• Complete blood count:
  • Acute phase: normocytic anemia, leukocytosis with neutrophilia.
  • Subacute phase: marked thrombocytosis (often >450,000/µL).
• Liver function: Mild to moderate elevation of transaminases, hypoalbuminemia.
• Urinalysis: Sterile pyuria.
• Cardiac markers: May be elevated in myocarditis or KDSS (e.g., troponin, BNP/NT-proBNP).

Imaging and Echocardiography

Transthoracic echocardiography is essential at baseline and follow-up to evaluate coronary arteries and cardiac function. Key findings include:

• Coronary artery dilatation or aneurysms (assessed using Z-scores based on body surface area).
• Decreased LV systolic function consistent with myocarditis or KDSS.
• Pericardial effusion, valvular regurgitation (often MR).

Coronary artery lesions are classified by Z-score (e.g., small, medium, or giant aneurysms), which is crucial for risk stratification and long-term management.^{[2], [1]}

Diagnostic Approach and Differentials

The diagnostic algorithm for suspected KD involves:

• Assessing duration of fever and principal clinical features.
• Evaluating inflammatory markers and other supportive labs.
• Performing echocardiography, especially if incomplete criteria or infants with unexplained fever and inflammation.

Important differentials include viral exanthems (adenovirus, measles, enterovirus), scarlet fever, staphylococcal or streptococcal toxic shock syndromes, drug reactions, MIS-C, systemic JIA, and other vasculitides. Overlap with MIS-C is notable, but MIS-C often presents in older children, with stronger association to SARS-CoV-2, more prominent GI and shock features, and higher rates of LV dysfunction relative to classic KD, although both can have coronary involvement.^{[4], [1]}

Management

Early treatment (ideally within the first 10 days of illness, and as soon as KD is suspected) significantly reduces the risk of coronary artery aneurysm formation.

First-Line Therapy

• Intravenous immunoglobulin (IVIG):
  • Standard dose: 2 g/kg as a single IV infusion over 8–12 hours.
  • Most effective when given within day 5–10 of illness; can be given later if there is ongoing fever/inflammation or evolving coronary involvement.
  • Mechanisms include modulation of Fc receptors, neutralization of immune complexes, and anti-inflammatory effects on cytokine networks and endothelium.^{[1], [2]}
• Aspirin:
  • High-dose phase (acute): Common regimens include 30–50 mg/kg/day up to 80–100 mg/kg/day divided q6h until the child is afebrile for 48–72 hours.
  • Low-dose phase: Then transition to 3–5 mg/kg/day once daily for 6–8 weeks, or longer if coronary abnormalities persist, for antiplatelet effect.

Management of IVIG-Resistant Kawasaki Disease

Approximately 10–20% of patients are IVIG-resistant, defined by persistent or recrudescent fever ≥36 hours after completion of the first IVIG infusion. In these patients, the following strategies are considered:

• Repeat IVIG (2 g/kg).
• Systemic corticosteroids (e.g., IV methylprednisolone pulse or prednisolone regimen) as part of a step-up or combination approach; early steroid use may be considered in high-risk patients, based on risk-scoring systems and evolving data.^{[2], [1]}
• Biologic agents in refractory cases: IL-1 blockade (e.g., anakinra) and TNF-α inhibitors (e.g., infliximab) are being increasingly used, particularly in refractory or high-risk KD and in KD-MAS, guided by emerging data-driven algorithms.^{[2], [6]}

Management of Complications

• Coronary artery aneurysms:
  • Antiplatelet therapy (low-dose aspirin) continued long-term if aneurysms persist.
  • For large/giant aneurysms, consider adding anticoagulation (e.g., warfarin or LMWH) to reduce thrombotic risk.
  • Beta-blockers and statins may be used in selected patients to reduce myocardial oxygen demand and modulate endothelial function; long-term cardiology follow-up is essential.^{[2], [1]}
• KD shock syndrome (KDSS):
  • Requires hemodynamic support (fluid resuscitation, inotropes/vasoactive agents), intensive monitoring, and standard KD therapy (IVIG, aspirin) plus adjunct immunomodulation as needed.
  • Consider early corticosteroids or biologics in severe inflammatory phenotypes.^{[5], [1]}
• KD-associated MAS:
  • Treated with high-dose corticosteroids, often with adjunctive biologic agents (e.g., IL-1 blockade), guided by sJIA-MAS criteria and a step-up therapeutic approach.^[6]

Follow-Up and Long-Term Management

Echocardiography is typically repeated at 1–2 weeks and 4–6 weeks after disease onset, with further follow-up determined by coronary status. Children with no coronary involvement and complete resolution can often have aspirin discontinued at 6–8 weeks. Those with persistent coronary lesions require long-term cardiology follow-up, risk factor modification, and individualized antithrombotic regimens. Long-term surveillance may include stress testing and advanced imaging (CT or MR angiography) in those with significant coronary disease.^{[2], [1]}

Key Clinical Pearls for Exams and Practice

• Think KD in any child with ≥5 days of fever and mucocutaneous findings (conjunctivitis, rash, strawberry tongue, extremity changes, cervical lymphadenopathy), especially aged <5 years.
• Incomplete KD is high-yield: Infants can present with prolonged fever and irritability with few mucocutaneous signs; use labs and echocardiography liberally in this group because they are at high risk for coronary aneurysms.
• IVIG within the first 10 days dramatically decreases coronary aneurysm risk; do not delay therapy waiting for complete criteria if suspicion is high.
• Coronary involvement defines prognosis. Serial echocardiography and appropriate long-term cardiology follow-up are essential, especially for children with aneurysms.
• Differentiate KD from MIS-C and toxic shock: MIS-C tends to affect older children, has closer temporal relation to SARS‑CoV‑2, more GI involvement, and higher LV dysfunction, while classic KD centers in toddlers with typical mucocutaneous signs and earlier, prominent coronary involvement.^{[4], [1]}
• Shock and MAS variants (KDSS, KD-MAS) represent the severe end of the spectrum and require aggressive hemodynamic and immunomodulatory management.
• Atypical features such as Grisel’s syndrome (non-traumatic atlantoaxial subluxation) can rarely precede overt KD and KDSS; unexplained neck pain with fever and inflammation in a child should prompt consideration of KD in the differential.^[5]
• Data-driven, risk-stratified approaches using clinical, laboratory, and imaging markers are increasingly guiding personalized immunomodulation beyond IVIG and aspirin, including early steroids and biologics in high-risk KD.^{[2], [6]}

Summary

Kawasaki disease is an acute pediatric medium-vessel vasculitis with a hallmark risk of coronary artery aneurysms. Early recognition, timely IVIG and aspirin, and risk-stratified immunomodulation are key to reducing cardiovascular morbidity. For medical students and trainees, mastery of the clinical criteria, awareness of incomplete presentations, and understanding of evolving management strategies—including those for KDSS and KD-MAS—are crucial for exams and clinical practice in pediatrics and cardiology.